Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 7, Pages 996
Publisher
MDPI AG
Online
2019-07-17
DOI
10.3390/cancers11070996
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells
- (2019) Jesus Luna et al. Cancers
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
- (2019) Kurt A. Schalper et al. NATURE MEDICINE
- Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors–Human Leukocyte Antigen Ligand Mismatch and Activation Receptor–Ligand Interactions
- (2018) Heleen Neeltje Haspels et al. Frontiers in Immunology
- Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5
- (2018) Mattias Carlsten et al. OncoImmunology
- Dual role of autophagy in hallmarks of cancer
- (2017) Shikha Satendra Singh et al. ONCOGENE
- Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner
- (2017) Silvia Würstle et al. Oncology Letters
- Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients
- (2017) M. Bahador et al. OncoImmunology
- Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy
- (2016) J. Y. Yoo et al. CLINICAL CANCER RESEARCH
- Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity
- (2016) C. M. Suryadevara et al. CLINICAL CANCER RESEARCH
- A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas
- (2016) Jeffrey J. Raizer et al. JOURNAL OF NEURO-ONCOLOGY
- Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells
- (2015) Hans Jiro Becker et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Activation-Specific Metabolic Requirements for NK Cell IFN-γ Production
- (2015) Molly P. Keppel et al. JOURNAL OF IMMUNOLOGY
- Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
- (2015) Andrea Gras Navarro et al. Frontiers in Immunology
- NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival
- (2014) Andrea Gras Navarro et al. JOURNAL OF IMMUNOLOGY
- Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation
- (2014) C Kao et al. Cell Death & Disease
- Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level
- (2013) Justyna Kmiecik et al. JOURNAL OF NEUROIMMUNOLOGY
- Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
- (2013) X Sui et al. Cell Death & Disease
- Nonclassical Antigen-Processing Pathways Are Required for MHC Class II-Restricted Direct Tumor Recognition by NY-ESO-1-Specific CD4+ T Cells
- (2013) J. Matsuzaki et al. Cancer Immunology Research
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules
- (2012) P. Parham et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma
- (2011) Agnete Svendsen et al. ACTA NEUROPATHOLOGICA
- Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis
- (2011) T. Unterkircher et al. CLINICAL CANCER RESEARCH
- The dual role of autophagy in cancer
- (2011) Eeva-Liisa Eskelinen CURRENT OPINION IN PHARMACOLOGY
- Induction of autophagy in temozolomide treated malignant gliomas
- (2011) Manabu Natsumeda et al. NEUROPATHOLOGY
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
- (2010) S. Cooley et al. BLOOD
- Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics
- (2010) Camilla Krakstad et al. Molecular Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma
- (2008) S. Armeanu et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now